CD8A and neoplasm: Several BsAbs have successfully been approved, sharing common characteristics such as target specificity to cell types (tumor cells, endothelial cells, and immune-tolerant CD8+T cells) prevalent within the tumor microenvironment while exhibiting lower expression in normal tissues, thereby ensuring a higher safety margin.